The potential reclassification of marijuana from a Schedule I to a Schedule III drug could significantly impact the pre-roll industry. This article explores the potential benefits of reclassification, including reduced tax burdens, increased access to banking, and opportunities for research and development. It also highlights the importance of preparing for increased competition and strategizing for future success.